Vegatone | PDE5 inhibitor | Film-coated and chewable tablets
Vegatone-25: Sildenafil Citrate equivalent to Sildenafil 25 mg (film-coated).
Vegatone-50: Sildenafil Citrate equivalent to Sildenafil 50 mg (film-coated).
Vegatone-100: Sildenafil Citrate equivalent to Sildenafil 100 mg (film-coated).
Vegatone-100 C: Sildenafil Citrate equivalent to Sildenafil 100 mg (uncoated chewable).
Categories: Pharmaceutical Exporter India · Pharmaceutical Formulations India · WHO GMP Certified Formulations
Sildenafil Citrate Tablets is listed for pharmaceutical business-to-business enquiries. Exact active ingredients, formulation, strength, pack configuration and manufacturer details should be confirmed against the product label and approved technical documentation before ordering.
Sildenafil is a phosphodiesterase type 5 (PDE5) inhibitor used for erectile dysfunction (ED). Sildenafil is also used in specific formulations and prescribed regimens for pulmonary arterial hypertension (PAH), but these indications and dosing schedules are not interchangeable. Healthy Life Pharma Pvt. Ltd. is identified as the manufacturer and Healthy Inc as exporter in the supplied product brief; verify credentials and registrations before publication.
| Brand / product | Strength | Form | Composition |
|---|---|---|---|
| Vegatone-25 | 25 mg | Film-coated tablet | Sildenafil Citrate equivalent to Sildenafil 25 mg |
| Vegatone-50 | 50 mg | Film-coated tablet | Sildenafil Citrate equivalent to Sildenafil 50 mg |
| Vegatone-100 | 100 mg | Film-coated tablet | Sildenafil Citrate equivalent to Sildenafil 100 mg |
| Vegatone-100 C | 100 mg | Uncoated chewable tablet | Sildenafil Citrate equivalent to Sildenafil 100 mg |
| Unbranded Sildenafil Citrate tablets | 100 mg | Film-coated tablet | Sildenafil Citrate equivalent to Sildenafil 100 mg; metallic red oxide colour and excipients as supplied |
Therapeutic class: PDE5 inhibitor. SKU: Sildenafil Tablets. Packaging, shelf life and market standard: subject to approved product documentation. A 20 mg PAH product is discussed in the background description but its availability is not confirmed by the supplied compositions.
Key formulation considerations include sildenafil citrate identity and potency, particle-size control where required, blend and content uniformity, dissolution, stability and film-coat integrity. The 100 mg chewable formulation requires separate palatability, disintegration and performance evaluation. Specific micronization processes, branded coatings, tablet colour and onset claims must be supported by product-specific validation.
Quality testing should follow the approved product specification and applicable pharmacopoeial or registered methods. Relevant controls include identity, assay, dosage-unit uniformity, dissolution, impurities, packaging compatibility and stability. Numerical release limits and a claimed 36-month shelf life should not be published without supporting approved data.
Sildenafil inhibits PDE5, helping preserve cyclic GMP (cGMP). In erectile dysfunction, this supports relaxation of penile smooth muscle and blood flow in response to sexual stimulation. In PAH, sildenafil can relax pulmonary blood vessels and improve exercise capacity in appropriate patients. ED tablets must not be assumed interchangeable with a PAH regimen. Indications depend on local regulatory approval.
For business-to-business supply, request the current manufacturing licence, product registration status, GMP evidence, certificate of analysis, stability documentation, packaging specifications and dossier availability. WHO-GMP certification, Star Export House status, COPP, Free Sale Certificate and shipping terms require verification with the supplier before commercial use.
Vegatone-25, Vegatone-50 and Vegatone-100 are film-coated tablets; Vegatone-100 C is an uncoated chewable tablet.
Yes, but the indication, product and dose regimen differ. The supplied products are not confirmed as registered PAH formulations.
No. Concurrent nitrate use can cause a dangerous fall in blood pressure.
For ED, sexual stimulation is needed for its erectile effect.
Prescription medicine. For ED, a commonly prescribed starting dose is 50 mg taken approximately one hour before sexual activity, with clinician-directed adjustment to 25 mg or 100 mg and no more than one dose per day. Individual requirements and contraindications vary. PAH uses a different clinician-supervised regimen and product approval. Do not use ED dosing to treat PAH. Follow the specific approved instructions for the chewable product rather than assuming the same administration as film-coated tablets.
Common adverse effects include headache, flushing, indigestion, nasal congestion, dizziness and temporary visual changes. Never combine sildenafil with nitrates (including nitroglycerin or isosorbide) or riociguat because severe hypotension may occur. Caution is also needed with alpha-blockers, some CYP3A4 inhibitors and cardiovascular disease. Seek urgent medical care for chest pain, sudden vision or hearing loss, or an erection lasting more than four hours. Cardiovascular suitability and use in significant liver or kidney disease require prescriber assessment.
Keep tablets in their original labelled packaging, protected from excessive heat and moisture and out of reach of children. Follow the approved label for exact temperature limits and expiry. The supplied description proposes storage below 30°C, but final storage requirements must be verified for each formulation and market.
For professional and B2B reference. Prescription use only. Product availability, certifications and market-specific approvals require verification.